OCUL: Ocular Therapeutix Inc. filed SEC Form 8-K: Regulation FD Disclosure
Stocks in this Quantisnow insightHealth Care
Historical context for OCUL
Across the 14 sessions after earlier OCUL headlines, the stock closed higher 9 times and lower 5 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | OCUL | SPY |
|---|---|---|---|
| Feb 24, 2026 | Ocular Therapeutix™ to Participate in March Investor Conferences | +6.5% | +0.7% |
| Feb 23, 2026 | Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations | +8.1% | -1.0% |
| Feb 17, 2026 | Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMDand 1 other headline that session | -21.3% | +0.2% |
| Feb 9, 2026 | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +2.9% | +0.5% |
| Feb 5, 2026 | Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | +4.2% | -1.2% |
| Jan 26, 2026 | Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | +6.0% | +0.5% |
Quantisnow market dataNASDAQ
OCUL
Ocular Therapeutix Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for OCUL
Full OCUL profile on Quantisnow Follow OCUL and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time